sorafenib + doxorubicin

This combination therapy involves the systemic administration of sorafenib, a multi-kinase inhibitor, alongside Transcatheter Arterial Chemoembolization (TACE) using doxorubicin. Sorafenib targets tumor cell proliferation and angiogenesis by inhibiting Raf kinase and vascular endothelial growth factor receptors (VEGFR). Doxorubicin, a cytotoxic anthracycline, is delivered directly to the hepatic artery supplying the tumor, where it intercalates into DNA and inhibits topoisomerase II. The combination is primarily investigated for the treatment of intermediate-stage hepatocellular carcinoma (HCC), with the rationale that sorafenib may counteract the surge in pro-angiogenic factors (like VEGF) typically observed following the ischemic insult caused by TACE.

Brand names

Nexavar

Other names

sorafenib + TACEsorafenib + doxorubicin lipiodol emulsionSTART trial regimen